Gain Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
GANX$1.09+5.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended December 31, | ||||||
| · 2024 · 2023 | ||||||
| Revenues: · · · | ||||||
| Collaboration revenues | | $— | | $55,180 | ||
| Other income | | | — | | — | |
| Total revenues | | | — | | | 55,180 |
| | | | | | | |
| Operating expenses: | | | ||||
| Research and development | | (10,791,058) | | (11,520,613) | ||
| General and administrative | | (9,559,534) | | (10,787,700) | ||
| Total operating expenses | | | (20,350,592) | | | (22,308,313) |
| | | | | | | |
| Loss from operations | | | (20,350,592) | | | (22,253,133) |
| | | | | | | |
| Other income (expense): | | | ||||
| Interest income, net | | 357,096 | | 494,234 | ||
| Foreign exchange gain (loss), net | | 119,120 | | (429,346) | ||
| Loss before income tax | | | (19,874,376) | | | (22,188,245) |
| | | | | | | |
| Income tax | | (536,815) | | (79,275) | ||
| | | | | | | |
| Net loss | | $(20,411,191) | | $(22,267,520) | ||
| | | | | | | |
| Net loss per shares: | | | ||||
| Net loss per share attributable to common stockholders - basic and diluted | | $(0.89) | | $(1.71) | ||
| Weighted average common stock - basic and diluted | | 22,881,415 | | 13,011,361 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.